» Articles » PMID: 37668735

Cutting-edge Regenerative Therapy for Hirschsprung Disease and Its Allied Disorders

Abstract

Hirschsprung disease (HSCR) and its associated disorders (AD-HSCR) often result in severe hypoperistalsis caused by enteric neuropathy, mesenchymopathy, and myopathy. Notably, HSCR involving the small intestine, isolated hypoganglionosis, chronic idiopathic intestinal pseudo-obstruction, and megacystis-microcolon-intestinal hypoperistalsis syndrome carry a poor prognosis. Ultimately, small-bowel transplantation (SBTx) is necessary for refractory cases, but it is highly invasive and outcomes are less than optimal, despite advances in surgical techniques and management. Thus, regenerative therapy has come to light as a potential form of treatment involving regeneration of the enteric nervous system, mesenchyme, and smooth muscle in affected areas. We review the cutting-edge regenerative therapeutic approaches for managing HSCR and AD-HSCR, including the use of enteric nervous system progenitor cells, embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells as cell sources, the recipient intestine's microenvironment, and transplantation methods. Perspectives on the future of these treatments are also discussed.

Citing Articles

Causes and consequences: development and pathophysiology of Hirschsprung disease.

Burns A, Goldstein A World J Pediatr Surg. 2024; 7(4):e000903.

PMID: 39600627 PMC: 11590806. DOI: 10.1136/wjps-2024-000903.


Robotic intersphincteric resection for low rectal cancer: a cumulative sum analysis for the learning curve.

Gao Y, Pan H, Ye J, Ruan H, Jiang W, Chi P Surg Today. 2024; 54(11):1329-1336.

PMID: 38717597 DOI: 10.1007/s00595-024-02841-x.

References
1.
Rao M, Gershon M . The bowel and beyond: the enteric nervous system in neurological disorders. Nat Rev Gastroenterol Hepatol. 2016; 13(9):517-28. PMC: 5005185. DOI: 10.1038/nrgastro.2016.107. View

2.
Klein M, Varga I . Hirschsprung's Disease-Recent Understanding of Embryonic Aspects, Etiopathogenesis and Future Treatment Avenues. Medicina (Kaunas). 2020; 56(11). PMC: 7697404. DOI: 10.3390/medicina56110611. View

3.
Taguchi T, Obata S, Ieiri S . Current status of Hirschsprung's disease: based on a nationwide survey of Japan. Pediatr Surg Int. 2017; 33(4):497-504. DOI: 10.1007/s00383-016-4054-3. View

4.
Muto M, Matsufuji H, Taguchi T, Tomomasa T, Nio M, Tamai H . Japanese clinical practice guidelines for allied disorders of Hirschsprung's disease, 2017. Pediatr Int. 2018; 60(5):400-410. DOI: 10.1111/ped.13559. View

5.
RAVITCH M . Pseudo Hirschsprung's disease. Ann Surg. 1958; 147(6):781-95. PMC: 1450736. View